Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jul;94(7):2928-2930.
doi: 10.1002/jmv.27740. Epub 2022 Apr 12.

Melatonin use for SARS-CoV-2 infection: Time to diversify the treatment portfolio

Russel J Reiter  1 , Ramaswamy Sharma  1 , Dun-Xian Tan  1 , Richard L Neel  2 , Fedor Simko  3 , Walter Manucha  4 , Sergio Rosales-Corral  5 , Daniel P Cardinali  6
Affiliations
Comment

Melatonin use for SARS-CoV-2 infection: Time to diversify the treatment portfolio

Russel J Reiter et al. J Med Virol. 2022 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Melatonin intervenes at several levels to reduce the severity of an infection mediated by SARS‐CoV‐2. Melatonin limits the entrance of the virus into cells as well as its intracellular replication, thereby reducing the total viral load. Moreover, melatonin functions as an anti‐inflammatory molecule to lower the cytokine storm and as a potent antioxidant to curtail the cellular damage resulting from excessive free radical generation. These combined actions lead to decreased multiorgan failure and mortality. Thus, melatonin's protective actions are direct more toward improving the resistance of the individual rather than against the virus. Evidence supporting these outcomes is provided by both the results of experimental studies and of clinical trials. SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2
See this image and copyright information in PMC

Comment on

References

    1. Lan SH, Lee HZ, Chao CM, Chang SP, Lu LC, Lai CC. Efficacy of melatonin in the treatment of patients with COVID‐19: a systematic review and meta‐analysis of randomized controlled trials. J Med Virol. 2022;94:2102‐2107. 10.1002/jmv.27595 - DOI - PMC - PubMed
    1. Alizadeh Z, Keyhanian N, Ghaderkhani S, Dashti‐Khavidaki S, Shokouhi Shoormasti R, Pourpak Z. A pilot study on controlling coronavirus disease 2019 (COVID‐19) inflammation using melatonin supplement. Iran J Allergy Asthma Immunol. 2021;20(4):494‐499. - PubMed
    1. Farnoosh G, Akbariqomi M, Badri T, et al. Efficacy of a low dose of melatonin as an adjunctive therapy in hospitalized patients with COVID‐19: a randomized, double‐blind clinical trial. Arch Med Res. 2022;53:79‐85. 10.1016/j.arcmed.2021.06.006 - DOI - PMC - PubMed
    1. Mousavi SA, Heydari K, Mehravaran H, et al. Melatonin effects on sleep quality and outcomes of COVID‐19 patients: an open‐label, randomized, controlled trial. J Med Virol. 2021;94(1):263‐271. 10.1002/jmv.27312 - DOI - PMC - PubMed
    1. Castillo RR, Quizon GRA, Juco MJM, et al. Melatonin as adjuvant treatment for coronavirus disease 2019 pneumonia patients requiring hospitalization (MAC‐19 PRO): a case series. Melatonin Res. 2020;3:297‐310. 10.32794/mr11250063 - DOI

LinkOut - more resources